Shenzhen BioScien in-licensed greater China rights to an immunotherapeutic vaccine for prostate cancer from Generex Biotech of the US in a $5 million agreement. In a Phase I trial, conducted by Generex’s subsidiary Antigen Express, AE37 produced an activation of T cells in patients with prostate cancer. Generex said the activation was robust, long-term, and specific. BioScien will develop the drug for mainland China plus Taiwan, Hong Kong and Macau.
Source: China Biotoday
